ClinicalTrials.gg
CompletedNCT04793204Updated Oct 26, 2024

A Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects

A Phase 1 interventional study of fezolinetant in Healthy Volunteers, sponsored by Astellas Pharma China, Inc.. Completed at 1 site in China. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by Astellas Pharma China, Inc. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The purpose of this study is to evaluate the pharmacokinetics and safety of fezolinetant after single-dose and multiple dose administration in healthy Chinese female participants.

Read the detailed description

Participants will undergo screening evaluations to determine their eligibility within 21 days prior to the study enrollment.

Participants will be admitted to the clinical unit a day before administration (day -1) and will be confined in the clinical unit until 48 hours after last administration (day 18).

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Fezolinetant
  • Pharmacokinetics
  • ESN364
  • Healthy Volunteer
03

In context

Lead sponsor

Astellas Pharma China, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a (BMI) range of > 19 kg/m\^2 and ≤ 24.9 kg/m\^2.
  • Subject has a body weight at screening ≥ 45.0 kg.
  • Subject must either:

    • Be of nonchildbearing potential: (defined as at least 1 year without any menses for which there is no other obvious pathological or physiological cause) prior to screening, or documented surgically sterile (e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy)
    • Or, if of , agree not to try to become pregnant during the study and for 30 days after the final study drug administration; and have a negative pregnancy test at screening and day -1; and if heterosexually active, agree to consistently use 1 form of effective starting at screening and throughout the study period and for 30 days after the final study drug administration. If male partner has undergone effective surgical sterilization (vasectomy or bilateral orchiectomy), it is not necessary to implement the birth control method.
  • Subject must agree not to breastfeed starting at screening and throughout the study period, and for 30 days after the final study drug administration.
  • Subject must not donate ova starting at screening and throughout the study period, and for 30 days after the final study drug administration.
  • Subject agrees not to participate in another interventional study while participating in the present study, defined as 84 days prior to the screening test until completion of the last study visit.

Exclusion criteria

Exclusion Criteria:

  • Subject has been pregnant within 6 months (including delivery or abortion) or has been breast feeding within 3 months prior to the screening test.
  • Subject has had previous exposure with fezolinetant.
  • Subject has any history of allergic conditions (including drug allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to study drug administration.
  • Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or .
  • Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (noncutaneous) infection within 1 week prior to day -1.
  • Subject has any of the liver function tests ( [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], gamma-glutamyl transferase [GGT] and total [TBL]) above the at screening or day -1. In such a case, the assessment is allowed to repeated only once.
  • Subject applies to any of the following concerns with regard to tuberculosis.

    • History of active tuberculosis
    • Significant abnormalities detected in a chest X-ray test at Screening
    • Contact with infectious tuberculous patients
  • Subject had clinically significant abnormality in their laboratory value at screening test and on day -1.
  • Subject who deviated from the following range of vital signs or routine 12-lead (ECG) results at screening test or day -1. If corrected by Fridericia method (QTcF) exceeds the limits determined, ECG is allowed to be repeated once; if pulse rate or ear temperature exceeds the limits determined, the measurements of pulse and ear temperature are allowed to be repeated once; if the blood pressure exceed limits determined, the measurement of blood pressure should be repeated once. The final judgment should be based on the retest results.
  • Subject has a positive serology test for surface antigen (HBsAg), hepatitis B core (HBc) antibody, virus (HCV) antibodies, (HIV) antibody, syphilis and hepatitis A virus (HAV) antibodies (immunoglobulin M [IgM]) at screening.
  • Subject has used any drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, tricyclic antidepressants, phencyclidine, cocaine and opiates) within 3 months prior to day -1. Subject who has a history of drug abuse within 2 years prior to screening test.
  • Subject has used any prescribed or nonprescribed drugs (including vitamins, oral , hormone replacement therapy [HRT], natural and herbal remedies, e.g. St. John's Wort, Chinese medicine such as Heyan Kuntai Capsule) in 3 months prior to study drug administration, except for occasional use of paracetamol (up to 2 g/day) and topical dermatological products, including products.
  • Subject has used any inducer of metabolism (e.g. barbiturates, rifampin) in 3 months prior to day -1.
  • Subject has a history of smoking within 3 months prior to day -1.
  • Subject whose daily caffeine consumption is ≥ 500 mg (500 mg of caffeine: about 800 mL of coffee, 1600 mL of black tea, 2500 mL of green tea, 5000 mL of cola).
  • Subject whose weekly alcohol consumption is ≥14 units* within 6 months prior to screening test, or who has a history of alcohol dependency, drug dependency, chemical dependency, or alcohol abuse within 2 years prior to screening test (*1 unit: approximately 360 mL of beer, 120 mL of wine, 30 mL of spirit).
  • Subject who has had blood sampled or donated blood during the following period.

    • Whole blood sample of ≥ 400 mL: from 90 days prior to screening test until hospital admission.
    • Whole blood sample of ≥ 200 mL: from 30 days prior to screening test until hospital admission.
    • Blood component donation: from 14 days prior to screening test until hospital admission.
  • Subject is employed by the sponsor, contract research organization (CRO), or study center associated with this study.
  • Subject is deemed unsuitable for participating in the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    fezolinetant

    A single oral dose of fezolinetant will be administered with water under fasting conditions on day 1 (low dose), day 4 (medium dose) and day 7 (high dose). From day 10 to day 15, the medium dose of fezolinetant will be administered with water after breakfast once daily. On day 16, the medium dose of fezolinetant will be administered with water under fasting conditions.

    Drug: fezolinetant

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events (AEs)

    Adverse events (AEs) will be coded using medical dictionary for regulatory activities (MedDRA). An AE is any untoward medical occurrence in a participant administered a study drug and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medical product whether or not considered related to the medical product. An AE is considered "serious" if, in the view of either the investigator or sponsor, the event: results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires hospitalization or prolongation to hospitalization, or other medically important event.

    Time frame: Up to day 41

  2. Number of participants with laboratory value abnormalities and/or adverse events (AEs)

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to day 41

  3. Number of participants with vital sign abnormalities and/or adverse events (AEs)

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to day 41

  4. Number of participants with rountine 12 lead electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)

    Number of participants with potentially clinically significant ECG values.

    Time frame: Up to day 41

  5. Pharmacokinetics (PK) of fezolinetant in plasma: AUC24

    Area under the concentration-time curve from the time of dosing to 24 hours (AUC24) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 7

  6. Pharmacokinetics (PK) of fezolinetant in plasma: AUCinf

    AUC from the time of dosing extrapolated to time infinity (AUCinf) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 7

  7. Pharmacokinetics (PK) of fezolinetant in plasma: AUCinf(%extrap)

    Percentage of extrapolated section of AUCinf (AUCinf(%extrap)) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 7

  8. Pharmacokinetics (PK) of fezolinetant in plasma: AUClast

    Area under the concentration time curve from the time of dosing to the last measurable concentration (AUClast) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 7

  9. Pharmacokinetics (PK) of fezolinetant in plasma: Ctrough

    Concentration immediately prior to dosing at multiple dosing (trough concentration) (Ctrough) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  10. Pharmacokinetics (PK) of fezolinetant in plasma: AUCtau

    AUC from the time of dosing to the start of the next dosing interval (AUCtau) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  11. Pharmacokinetics (PK) of fezolinetant in plasma: CL/F

    Apparent total clearance after extra-vascular dosing (CL/F) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  12. Pharmacokinetics (PK) of fezolinetant in plasma: Cmax

    Maximum concentration (Cmax) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  13. Pharmacokinetics (PK) of fezolinetant in plasma: PTR

    Peak-trough ratio (PTR) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  14. Pharmacokinetics (PK) of fezolinetant in plasma: Rac(AUC)

    Accumulation ratio calculated using AUC (Rac(AUC)) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  15. Pharmacokinetics (PK) of fezolinetant in plasma: Rac(Cmax)

    Accumulation ratio calculated using Cmax (Rac(Cmax)) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  16. Pharmacokinetics (PK) of fezolinetant in plasma: t1/2

    Terminal elimination half-life (t1/2) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  17. Pharmacokinetics (PK) of fezolinetant in plasma: tmax

    Time of the maximum concentration (tmax) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  18. Pharmacokinetics (PK) of fezolinetant in plasma: Vz/F

    Apparent volume of distribution during the terminal elimination phase after extra-vascular dosing (Vz/F) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  19. Pharmacokinetics (PK) of fezolinetant in plasma: Tlag

    Time-lag (Tlag) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  20. Pharmacokinetics (PK) of ES259564 in plasma: AUC24

    Area under the concentration-time curve from the time of dosing to 24 hours (AUC24) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 7

  21. Pharmacokinetics (PK) of ES259564 in plasma: AUCinf

    Area under the concentration time curve from the time of dosing extrapolated to time infinity (AUCinf) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 7

  22. Pharmacokinetics (PK) of ES259564 in plasma: AUCinf(%extrap)

    Percentage of extrapolated section of AUCinf (AUCinf(%extrap)) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 7

  23. Pharmacokinetics (PK) of ES259564 in plasma: AUClast

    Area under the concentration time curve from the time of dosing to the last measurable concentration (AUClast) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 7

  24. Pharmacokinetics (PK) of ES259564 in plasma: Ctrough

    Concentration immediately prior to dosing at multiple dosing (trough concentration) (Ctrough) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  25. Pharmacokinetics (PK) of ES259564 in plasma: AUCtau

    AUC from the time of dosing to the start of the next dosing interval (AUCtau) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  26. Pharmacokinetics (PK) of ES259564 in plasma: Cmax

    Maximum concentration (Cmax) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  27. Pharmacokinetics (PK) of ES259564 in plasma: PTR

    Peak-trough ratio (PTR) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  28. Pharmacokinetics (PK) of ES259564 in plasma: Rac(AUC)

    Accumulation ratio calculated using AUC (Rac(AUC)) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  29. Pharmacokinetics (PK) of ES259564 in plasma: Rac(Cmax)

    Accumulation ratio calculated using Cmax (Rac(Cmax)) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  30. Pharmacokinetics (PK) of ES259564 in plasma: t1/2

    Terminal elimination half-life (t1/2) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  31. Pharmacokinetics (PK) of ES259564 in plasma: tmax

    Time of the maximum concentration (tmax) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  32. Pharmacokinetics (PK) of ES259564 in plasma: MPR

    Metabolite to parent ratio (MPR) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

  33. Pharmacokinetics (PK) of ES259564 in plasma: Tlag

    Time-lag (Tlag) will be recorded from the pharmacokinetic (PK) plasma samples collected.

    Time frame: Up to day 16

07

Study locations

1 site
  • Site CN86001
    Bei'jing, China
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in May 2021, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2021
First posted
Mar 11, 2021
StartActual
Mar 24, 2021
Primary completionActual
May 21, 2021
CompletionActual
May 21, 2021
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04793204
Responsible party
Sponsor
First posted
Mar 11, 2021
Start date
Mar 24, 2021
Primary completion
May 21, 2021
Completion
May 21, 2021
Last update
Oct 26, 2024

Study contacts

Central Contact
study director · Astellas Pharma China, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fezolinetant

Start the discussion